Newron Pharmaceuticals Announces Positive Results for Evenamide in Schizophrenia Study

Newron Pharmaceuticals S.p.A. has disclosed further positive outcomes from its study 008A, targeting patients who show poor responses to second-generation antipsychotics. The international, randomized, double-blind study tested the efficacy and safety of evenamide as an adjunctive treatment, featuring significant improvements in both the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression of Change (CGI-C) by the study's conclusion on Day 29.

The study involved 291 patients and highlighted the tolerability of evenamide added to existing antipsychotic regimens, noting no significant increases in adverse effects compared to placebo. The data are compelling, particularly in revealing that benefits accrue over time, suggesting potential long-term treatment efficacy. This study stands as the first to demonstrate the effectiveness of a glutamate modulator in such a detailed, placebo-controlled environment for schizophrenia patients inadequately responsive to their current treatments.